2.71MMarket Cap-137P/E (TTM)
1.3000High1.2000Low134.13KVolume1.2500Open1.2900Pre Close167.45KTurnover6.05%Turnover RatioLossP/E (Static)2.24MShares17.200052wk High0.38P/B2.68MFloat Cap1.200052wk Low--Dividend TTM2.22MShs Float636800.0000Historical High--Div YieldTTM7.75%Amplitude1.2000Historical Low1.2480Avg Price1Lot Size
Altamira Therapeutics Stock Forum
Altamira Therapeutics Ltd. (Nasdaq: CYTO), a company focused on developing and commercializing RNA delivery technology for targets beyond the liver, recently announced the dissemination of positive results from its NASAR clinical trial with Bentri...
NEWS
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
NEWS
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
3 MINUTES AGO, 8:47 AM EDT
VIA GLOBENEWSWIRE
In an era where medical innovation is more critical than ever, a groundbreaking collaboration between Altamira Therapeutics Ltd. and Univercells Group has emerged, signaling a potential leap forward in the way vaccines are delivered. Announced on March 25, 2024, this partnership aims to ha...
No comment yet